Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Graypoint LLC

Posted by Defense World Staff on Apr 21st, 2023

Graypoint LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,577 shares of the company’s stock after purchasing an additional 1,186 shares during the period. Graypoint LLC’s holdings in Johnson & Johnson were worth $2,752,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Glassy Mountain Advisors Inc. acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $40,000. TD Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth $48,000. VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $52,000. Finally, Iron Horse Wealth Management LLC increased its stake in shares of Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.6 %

JNJ opened at $163.58 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $426.01 billion, a PE ratio of 24.27, a PEG ratio of 2.75 and a beta of 0.53. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $186.69. The firm has a 50-day moving average price of $157.48 and a two-hundred day moving average price of $166.96.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same quarter last year, the firm earned $2.67 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. As a group, equities analysts anticipate that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.91%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Insider Buying and Selling

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent analyst reports. Piper Sandler decreased their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. SVB Leerink reduced their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday. Morgan Stanley increased their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Guggenheim started coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.